AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50%

Study limitation reported by the research below: “The tislelizumab monotherapy arm (Arm C) was randomized at a smaller ratio (5:5:2) and any comparison to pembrolizumab is exploratory only.”